2026 Cholangiocarcinoma Foundation Annual Conference Abstracts
The Oncologist · 01.06.2026 · 31 (Supplement_1)
DOI: 10.1093/oncolo/oyag205.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 23.06.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction The 13th Annual Conference of the Cholangiocarcinoma Foundation (CCF) took place on May 1-3, 2026, in Salt Lake City, USA; this year’s conference also celebrated CCF’s 20th Anniversary. Themed Strength in Community: Every Patient Counts, it convened leading researchers, clinicians, patients, caregivers, advocates, and industry partners to explore the latest basic science, translational and clinical advancements in cholangiocarcinoma (CCA) and foster collaboration across the community. The conference, co-chaired by Dr Tim F Greten (NIH, MD, USA) and Dr Luke Boulter (University of Edinburgh, UK), consisted of three keynote presentations: 1. Therapy Resistance and Combination Strategies in CCA: Navigating Adaptive Responses and Lineage States (Dr Nabeel El-Bardeesy, Harvard); 2. Beyond Immune Checkpoint Blockade: Emerging Strategies (Dr Tak Mak, Princess Margaret Hospital, Canada); and 3. Research in CCA: Accomplishments, Advances, and Aspirations (Dr Gregory Gores, Mayo Clinic). There was a focus on basic science on Day 1, with multidisciplinary clinical aspects on Days 2 and 3, covering surgery, and locoregional and systemic therapies, including novel targets and agents in development. The patient voice is a key feature of the Conference; in addition to a Patient Day (Day 1), patients and caregivers shared their experiences during the plenary sessions, participated in discussions, and learned about the latest research in the poster session and the Clinical and Science Poster Walks, with posters requiring a lay summary. CCF helps to develop the next generation of researchers. Plenary sessions were co-chaired by early career investigators; they also presented their research as posters. Some were selected for oral presentations or speed talks. The 2026 CCF Fellows were announced at the Awards Ceremony, and the 2025 CCF Fellows gave oral presentations of their research. This supplement contains all accepted abstracts (as of April 10, 2026). Please note that some abstracts may have been withdrawn or rescheduled at authors’ request. In addition, The Oncologist is not able to accept previously published encore abstracts. These have been removed, although the Cholangiocarcinoma Foundation is grateful that this information was shared at the meeting with the clinical and patient community.
Zitieren
APA
(2026). 2026 Cholangiocarcinoma Foundation Annual Conference Abstracts. The Oncologist, 31(Supplement_1). https://doi.org/10.1093/oncolo/oyag205.001
Vancouver
2026 Cholangiocarcinoma Foundation Annual Conference Abstracts. The Oncologist. 2026;31(Supplement_1). doi:10.1093/oncolo/oyag205.001
BibTeX
@article{euvimed2026,
title = {2026 Cholangiocarcinoma Foundation Annual Conference Abstracts},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {Supplement_1},
doi = {10.1093/oncolo/oyag205.001}
}
EUVIMED